Alnuctamab

DRUG6 trials

Sponsors

Celgene International II S.a.r.l., Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Celgene, Icahn School of Medicine at Mount Sinai

Conditions

Multiple MyelomaRelapsed and/or Refractory Multiple MyelomaSystemic Lupus Erythematosus

Phase 1

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

RecruitingNCT06121843

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyMultiple Myeloma

Start: 2024-02-22End: 2028-08-01Target: 147Updated: 2026-02-18

A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Active, not recruitingNCT06163898

CelgeneMultiple Myeloma

Start: 2024-02-27End: 2025-05-30Target: 156Updated: 2025-04-04

Alnuctamab for Refractory SLE (LATTE Study)

RecruitingNCT07219563

Icahn School of Medicine at Mount SinaiSystemic Lupus Erythematosus

Start: 2026-03-01End: 2027-12-01Target: 21Updated: 2026-02-25

Phase 2

A Phase 1b/2a, Multicenter, Open-Label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination with Mezigdomide in Participants with Relapsed and/or Refractory Multiple Myeloma

WithdrawnCTIS2023-504367-16-00

Celgene International II S.a.r.l.Relapsed and/or Refractory Multiple Myeloma

Target: 14Updated: 2024-01-11

Phase 3

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

WithdrawnNCT06232707

CelgeneMultiple Myeloma

Start: 2024-05-03End: 2030-09-21Updated: 2024-05-31

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM

CompletedCTIS2023-509472-42-00

Celgene International II S.a.r.l.Relapsed and/or Refractory Multiple Myeloma

End: 2024-05-17Target: 177Updated: 2024-04-23

Related Papers

Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Blood2025-11-03